Efgartigimod Shows Benefit in AChR‑Antibody–Negative Generalized Myasthenia Gravis — New Data from ADAPT SERON
Phase 3 ADAPT SERON data show efgartigimod improves MG‑ADL scores in AChR‑Ab–negative gMG, with pronounced benefit in MuSK‑positive patients; results for triple‑seronegative disease were inconclusive. Safety profile was consistent with prior experience.